Examples include: peptide therapy (at high doses or long-term use) TB-500 (Thymosin Beta-4) VEGF-mimetic peptides Tesamorelin/peptide therapy (via IGF-1 pathways) Potential risks of prolonged use: Scar tissue overdevelopment Feeding abnormal or cancerous cell growth Disrupting blood flow in sensitive tissues (eyes, kidneys) Thats why we recommend cycles like: TB-500 : 610 weeks on, 4+ weeks off peptide therapy injections : short-term, with oral BPC for maintenance Tesamorelin/peptide therapy : rotated or paused to avoid overexposure Other Peptides That Benefit From Cycling Even non-angiogenic peptides benefit from breaks: Thymosin Alpha-1 : 5-week cycles, 23x per year GHK-Cu : 78 week cycles, followed by rest Semax & Dihexa : pulsed use to maintain brain sensitivity 5-Amino-1MQ : cycled after 23 rounds for metabolic reset Each protocol is tailored to half-life, tissue targets, and sensitivity feedback
Rub your palms together to warm up the lotion
Other options, including injections, shockwave therapy, vacuum devices, and implants, are typically considered when oral medication is insufficient or contraindicated
(2003) The actin binding site on thymosin beta4 promotes angiogenesis
It involves spraying the peptide solution into the nasal passages, allowing for absorption through the nasal mucosa and into the bloodstream
BPC-157 takes an elegant route here: it does not raise GH levels in the blood , but increases tissue sensitivity to GH via up-regulation of its receptors (GHR)